Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-01-31

Study Completion Date

2004-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a trial of treatment with tablets containing magnesium for leg cramps in pregnancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Magnesium and Alpha Lipoic Acid Supplementation in Reducing Premature Uterine Contractions

NCT02016495

Pregnancy

COMPLETED PHASE4

Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor

NCT00306462

Premature Birth Premature Labor

TERMINATED NA

Ritodrine in Oral Maintenance of Tocolysis After Active Preterm Labor

NCT00290173

Pregnancy

COMPLETED NA

Adverse Events With Magnesium Sulfate

NCT00005448

Lung Diseases

WITHDRAWN

Tocolytics Trial: Intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population

NCT00641784

Labor, Premature

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthy pregnant women between 18 and 36 weeks of pregnancy suffering from leg cramps at least twice a week were treated with magnesium tablets or placebo for two weeks, 120 mg x 3 daily.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cramps

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Magnesium tablet suplementation (1)

Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks)

Group Type ACTIVE_COMPARATOR

"Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks)

Intervention Type DRUG

120 mg x 3 or placebo

Placebo tablet suplementation (2)

Placebo (3 times daily for 2 weeks)

Group Type PLACEBO_COMPARATOR

"Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks)

Intervention Type DRUG

120 mg x 3 or placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

"Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks)

120 mg x 3 or placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nycoplus Magnesium tablets(R) Placebo tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women with recurrent leg cramps (at least twice a week).
* No disease according to helath certificate. Written participation consent must be signed.
* Linguistic ability demanded: Norwegian as the first language. Gestation length more than 17 weeks, less than 36 weeks.